| Bioactivity | DG70 (GSK1733953A), a biphenyl amide, is a respiration inhibitor in Mycobacterium tuberculosis, inhibits MenG activity with an IC50 value of 2.6 ± 0.6 μM. DG70 inhibits the catalytic methylation of Mycobacterium tuberculosis demethylmenaquinone methyltransferase enzymes. DG70 can be used for Tuberculosis (TB) research[1][2][3]. | ||||||||||||
| Target | IC50: 2.6 ± 0.6 μM (MenG) | ||||||||||||
| Name | DG70 | ||||||||||||
| CAS | 930470-97-6 | ||||||||||||
| Formula | C21H17ClFNO3 | ||||||||||||
| Molar Mass | 385.82 | ||||||||||||
| Appearance | 油状物 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Pujari V, et al. Mycobacterial MenG: Partial Purification, Characterization, and Inhibition. ACS Infect Dis. 2022 Dec 9;8(12):2430-2440. [2]. Adewumi AT, et al. Thompson loop: opportunities for antitubercular drug design by targeting the weak spot in demethylmenaquinone methyltransferase protein. RSC Adv. 2020 Jun 19;10(39):23466-23483. [3]. Sukheja P, et al. A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells. mBio. 2017 Feb 14;8(1):e02022-16. |